[go: up one dir, main page]

MA30037B1 - Compositions et procedes destines au traitement des troubles du snc - Google Patents

Compositions et procedes destines au traitement des troubles du snc

Info

Publication number
MA30037B1
MA30037B1 MA31013A MA31013A MA30037B1 MA 30037 B1 MA30037 B1 MA 30037B1 MA 31013 A MA31013 A MA 31013A MA 31013 A MA31013 A MA 31013A MA 30037 B1 MA30037 B1 MA 30037B1
Authority
MA
Morocco
Prior art keywords
treatment
compositions
methods
cns disorders
thienopyridinone
Prior art date
Application number
MA31013A
Other languages
English (en)
Inventor
Dale S Dhanoa
Oren M Becker
Silvia Noiman
Pradyumna Mohanty
Dongli Chen
Mercedes Lobera
Laurence Wu
Yael Marantz
Boaz Inbal
Alexander Heifetz
Shay Bar-Haim
Sharon Shacham
Original Assignee
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharm Inc filed Critical Epix Pharm Inc
Publication of MA30037B1 publication Critical patent/MA30037B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne d'une manière générale des modulateurs du récepteur de la thiénopyridinone 5-HT4 et en particulier l'utilisation de ces composés et de leurs compositions pharmaceutiques, par exemple pour le traitement, la modulation et/ou la prévention d'états physiologiques associés à l'action de la sérotonine tels que la maladie d'Alzheimer, les troubles de la cognition, la dépression et l'anxiété.
MA31013A 2005-11-10 2008-06-06 Compositions et procedes destines au traitement des troubles du snc MA30037B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/271,019 US7598265B2 (en) 2004-09-30 2005-11-10 Compositions and methods for treating CNS disorders

Publications (1)

Publication Number Publication Date
MA30037B1 true MA30037B1 (fr) 2008-12-01

Family

ID=37946751

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31013A MA30037B1 (fr) 2005-11-10 2008-06-06 Compositions et procedes destines au traitement des troubles du snc

Country Status (17)

Country Link
US (2) US7598265B2 (fr)
EP (1) EP1959954A2 (fr)
JP (1) JP2009515877A (fr)
KR (1) KR20080067001A (fr)
CN (1) CN101340908A (fr)
AR (1) AR057887A1 (fr)
AU (1) AU2006315854A1 (fr)
BR (1) BRPI0618493A2 (fr)
CA (1) CA2629312C (fr)
CR (1) CR10062A (fr)
EA (1) EA200801302A1 (fr)
IL (1) IL191168A0 (fr)
MA (1) MA30037B1 (fr)
NO (1) NO20082679L (fr)
TW (1) TW200735868A (fr)
WO (1) WO2007058805A2 (fr)
ZA (1) ZA200804951B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
MX2007008279A (es) 2005-01-25 2008-02-15 Epix Delaware Inc Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6.
GB0526258D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2445877B1 (fr) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Composés bicycliques et leurs procédés de fabrication et d'utilisation
RU2569056C2 (ru) * 2009-04-13 2015-11-20 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Соединения-агонисты рецептора 5-нт4 для лечения расстройств познавательной способности
US20230139125A1 (en) * 2021-02-04 2023-05-04 Richard Natrillo Dietary supplement for improving brain performance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069412A (en) * 1958-08-15 1962-12-18 Fmc Corp N-aminoazetidine and preparation thereof
CA933923A (en) * 1969-12-19 1973-09-18 Eichenberger Kurt Process for the manufacture of new thiopyranes
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2925175A1 (de) * 1979-06-22 1981-01-08 Basf Ag Verfahren zur herstellung von isatosaeureanhydriden
IT1203323B (it) 1987-02-02 1989-02-15 Hoechst Italia Spa Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
DE4023270A1 (de) * 1990-07-21 1992-02-06 Hoechst Ag Hydrophile mischpolymere sowie deren verwendung in der reprographie
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5155115A (en) 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5227387A (en) * 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4138820A1 (de) * 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
DE4208254A1 (de) * 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4227747A1 (de) * 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
JPH06239858A (ja) * 1993-02-16 1994-08-30 Otsuka Pharmaceut Co Ltd 末梢血管拡張剤
GB9306460D0 (en) 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE19636769A1 (de) * 1996-09-10 1998-03-12 Basf Ag 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
US6979309B2 (en) * 1997-02-14 2005-12-27 Nxstage Medical Inc. Systems and methods for performing blood processing and/or fluid exchange procedures
DE19724980A1 (de) * 1997-06-13 1998-12-17 Basf Ag 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
JPH11130777A (ja) 1997-08-13 1999-05-18 Takeda Chem Ind Ltd チエノピリジン誘導体、その中間体およびそれらの製造法
EP1020445B1 (fr) * 1997-10-02 2008-08-13 Eisai R&D Management Co., Ltd. Derives de pyridine condenses
WO1999043681A1 (fr) * 1998-02-26 1999-09-02 Neurogen Corporation Pyridines heteroaryle fondues substituees 4-(4-piperidylmethylamino); ligands du recepteur cerebral gaba
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
WO1999051932A2 (fr) * 1998-04-08 1999-10-14 Moshier Gary S Systeme, sous-systemes et composants pour la neutralisation de mines enterrees au moyen de munitions lancees
MXPA00011889A (es) * 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1173168A2 (fr) 1999-04-28 2002-01-23 Respiratorius AB Un compose pour l'utilisation d'un medicament destine au traitement de troubles de contraction bronchique
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
EP1229025A4 (fr) 1999-10-01 2003-04-09 Japan Energy Corp Nouveaux derives de quinazoline
EP1270568A1 (fr) 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-Méthyl-4-(3-éthoxy-9H-thioxanthène-ylidène)-pipéridine et son utilasition en tant qu'antagoniste du recepteur 5-HT2B et/ou H1
WO2003020728A1 (fr) * 2001-08-30 2003-03-13 Pharmacia & Upjohn Company Agents antiviraux a base de 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
WO2004034963A2 (fr) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methodes et compositions utilisant des inhibiteurs de la cholinesterase
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
WO2004017950A2 (fr) 2002-08-22 2004-03-04 Piramed Limited Inhibiteurs de phosphatidylinositol 3,5-biphosphate en tant qu'agents antiviraux
WO2004030629A2 (fr) 2002-10-01 2004-04-15 Predix Pharmaceuticals Nouveaux antagonistes de la neurokinine et leurs procedes d'utilisation
US7153858B2 (en) * 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
KR20060013370A (ko) * 2003-03-31 2006-02-09 프레딕스 파마슈티컬스 홀딩즈, 인코포레이티드 신규한 피페리디닐아미노-티에노[2,3-ｄ]피리미딘 화합물
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1680120A2 (fr) * 2003-11-03 2006-07-19 Probiodrug AG Combinaisons utiles au traitement de troubles neuronaux
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US20060084806A1 (en) * 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
MX2007008279A (es) * 2005-01-25 2008-02-15 Epix Delaware Inc Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6.
JP2009520688A (ja) * 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US20100184749A1 (en) 2006-10-12 2010-07-22 EPIX Delaware ,Inc. Benzothiadiazine compounds and their use
TW200836748A (en) 2006-11-17 2008-09-16 Epix Delaware Inc Adenosine analogs and their use

Also Published As

Publication number Publication date
KR20080067001A (ko) 2008-07-17
BRPI0618493A2 (pt) 2011-08-30
JP2009515877A (ja) 2009-04-16
CA2629312C (fr) 2014-08-12
WO2007058805A3 (fr) 2007-10-04
WO2007058805A2 (fr) 2007-05-24
US7598265B2 (en) 2009-10-06
EA200801302A1 (ru) 2009-02-27
NO20082679L (no) 2008-06-10
EP1959954A2 (fr) 2008-08-27
TW200735868A (en) 2007-10-01
AR057887A1 (es) 2007-12-26
CA2629312A1 (fr) 2007-05-24
CN101340908A (zh) 2009-01-07
ZA200804951B (en) 2009-04-29
IL191168A0 (en) 2008-12-29
US20110195953A1 (en) 2011-08-11
US20060234998A1 (en) 2006-10-19
AU2006315854A1 (en) 2007-05-24
CR10062A (es) 2009-05-14

Similar Documents

Publication Publication Date Title
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA51669B1 (fr) Modulateurs de tmem16a
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
TN2014000424A1 (fr) Agents pour le traitement de troubles impliquant la modulation des recepteurs de la ryanodine
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA31326B1 (fr) Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds
MA31016B1 (fr) Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine.
MA28746B1 (fr) Dérivés de quinazoline-4-yl-pipéridine et cinnoline-4-yl-pipéridine servant d'inhibiteurs de PDE10 pour le traitement de troubles du SNC
TNSN07258A1 (fr) Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
EP2268647A4 (fr) Composés et compositions pour la détection et le traitement de la maladie d'alzheimer et des troubles associés
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa